Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

OncoImmunology

Volumn 5, Issue 11, 2016, Pages

  Kyte, Jon Amund ^a   Aamdal, Steinar ^a   Dueland, Svein ^a   Sæbøe Larsen, Stein ^a   Inderberg, Else Marit ^a   Madsbu, Ulf Erik ^a   Skovlund, Eva ^b   Gaudernack, Gustav ^a   Kvalheim, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cancer vaccine; clinical outcome; dendritic cell; melanoma; mRNA; survival; T cell

Indexed keywords

CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; IPILIMUMAB; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MELANOMA VACCINE; MESSENGER RNA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG SAFETY; ECHOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MELANOMA; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; RNA EXTRACTION; T LYMPHOCYTE;

EID: 84994111950     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1232237     Document Type: Article

References (72)

1. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26(4):527-34; PMID:18235113; doi:10.1200/JCO.2007.12.7837
2. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma:a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4(12):748-59; PMID:14662431; doi:10.1016/S1470-2045(03)01280-4
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; doi:10.1056/NEJMoa1003466
4. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948):1109-17; PMID:25034862; doi:10.1016/S0140-6736(14)60958-2
5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1):23-34; PMID:26027431; doi:10.1056/NEJMoa1504030
6. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015; 21(4):712-20; PMID:25524312; doi:10.1158/1078-0432.CCR-14-2468
7. Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005; 12(6):579-91; PMID:15818380; doi:10.1038/sj.cgt.7700837
8. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-8; PMID:25765070; doi:10.1126/science.aaa1348
9. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348(6230):69-74; PMID:25838375; doi:10.1126/science.aaa4971
10. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280):1463-9; PMID:26940869; doi:10.1126/science.aaf1490
11. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17(13):4550-7; PMID:21498393; doi:10.1158/1078-0432.CCR-11-0116
12. Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Holmich LR, Hendel HW, Met O, Andersen MH, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 2016; 22(15):3734-45; PMID:27006492; doi:10.1158/1078-0432.CCR-15-1879
13. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201(2):249-57; PMID:15657294; doi:10.1084/jem.20041378
14. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003; 9(3):998-1008; PMID:12631598
15. Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012; 1(5):670-86; PMID:22934259; doi:10.4161/onci.20426
16. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33(25):2780-8; PMID:26014293; doi:10.1200/JCO.2014.58.3377
17. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13(10):905-18; PMID:16710345; doi:10.1038/sj.cgt.7700961
18. Kyte JA, Kvalheim G, Lislerud K, Thor Straten P, Dueland S, Aamdal S, Gaudernack G. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2007; 56(5):659-75; PMID:16947019; doi:10.1007/s00262-006-0222-y
19. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978; 75(10):5132-6; PMID:154105; doi:10.1073/pnas.75.10.5132
20. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59(1):56-8; PMID:9892184; doi:10.1080/2162402X.2015.1057673
21. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93(7):749-56; PMID:16136047; doi:10.1038/sj.bjc.6602761
22. Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, et al. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology 2016; 5(1):e1057673; PMID:26942068; doi:10.1080/2162402X.2015.1057673
23. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, et al. Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology 2015; 4(4):e998538; PMID:26137416; doi:10.1080/2162402X.2014.998538
24. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009; 58(10):1609-26; PMID:19221745; doi:10.1007/s00262-009-0670-2
25. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide:a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17(13):4568-80; PMID:21586625; doi:10.1158/1078-0432.CCR-11-0184
26. Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ. Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. Oncoimmunology 2016; 5(1):e1067745; PMID:26942087; doi:10.1080/2162402X.2015.1067745
27. Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein:implication for cancer immunotherapy. Clin Cancer Res 2005; 11(15):5566-71; PMID:16061874; doi:10.1158/1078-0432.CCR-05-0699
28. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136(7):2348-57; PMID:2419430
29. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004; 22(14):2808-15; PMID:15254048; doi:10.1200/JCO.2004.01.074
30. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96(9):3102-8; PMID:11049990
31. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002; 8(4):1021-32; PMID:11948109
32. Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination:a phase I trial in metastatic melanoma. Clin Cancer Res 2004; 10(16):5381-90; PMID:15328176; doi:10.1158/1078-0432.CCR-04-0602
33. Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 2004; 53(7):651-8; PMID:14999431; doi:10.1007/s00262-003-0495-3
34. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61(17):6451-8; PMID:11522640
35. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60(4):1028-34; PMID:10706120
36. Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P, Tang ML, Ashley DM. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005; 103(6):1280-91; PMID:15693021; doi:10.1002/cncr.20911
37. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4(3):328-32; PMID:9500607; doi:10.1038/nm0398-328
38. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63(9):2127-33; PMID:12727829
39. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ, Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001; 61(2):641-6; PMID:11212262
40. Brown K, Gao W, Alber S, Trichel A, Murphey-Corb M, Watkins SC, Gambotto A, Barratt-Boyes SM. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 2003; 171(12):6875-82; PMID:14662894; doi:10.4049/jimmunol.171.12.6875
41. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-Cell function in melanoma patients. J Clin Oncol 2003; 21(20):3826-35; PMID:14551301; doi:10.1200/JCO.2003.04.042
42. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17(17):5725-35; PMID:21771874; doi:10.1158/1078-0432.CCR-11-1261
43. Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 2015; 4(8):e1019197; PMID:26405571; doi:10.1080/2162402X.2015.1019197
44. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, Saeboe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62(9):1499-509; PMID:23817721; doi:10.1007/s00262-013-1453-3
45. Schreibelt G, Bol KF, Aarntzen EH, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. Oncoimmunology 2013; 2(6):e24440; PMID:23894702; doi:10.4161/onci.24440
46. Saebøe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002; 259(1-2):191-203; PMID:11730854; doi:10.1016/S0022-1759(01)00506-3
47. Benteyn D, Heirman C, Thielemans K, Bonehill A. Engineering WT1-encoding mRNA to increase translational efficiency in dendritic cells. Methods Mol Biol 2016; 1428:115-23; PMID:27236795; doi:10.1007/978-1-4939-3625-0_7
48. Su W, Slevin MK, Marzluff WF, Rhoads RE. Synthetic mRNA with superior properties that mimics the intracellular fates of natural histone mRNA. Methods Mol Biol 2016; 1428:93-114; PMID:27236794; doi:10.1007/978-1-4939-3625-0_6
49. Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, Darzynkiewicz E, Huber C, Tureci O, Sahin U. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Therapy 2010; 17(8):961-71
50. Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Francois V, Colau D, van der Bruggen P, Neyns B, Thielemans K. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009; 15(10):3366-75; PMID:19417017; doi:10.1158/1078-0432.CCR-08-2982
51. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18(19):5460-5470; PMID:22896657; doi:10.1158/1078-0432.CCR-11-3368
52. Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 2016; 34(12):1330-8; PMID:26926680; doi:10.1200/JCO.2015.63.4121
53. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519(7543):366-369; PMID:25762141; doi:10.1038/nature14320
54. Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, et al. CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Oncoimmunol 2016; 5(6):e1168555; PMID:27471645; doi:10.1080/2162402X.2016.1168555
55. Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ, Frankenberger B. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010; 185(1):738-47; PMID:20511554; doi:10.4049/jimmunol.1000060
56. Spranger S, Frankenberger B, Schendel DJ. NOD/scid IL-2Rg(null) mice:a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med 2012; 10:30; PMID:22364226; doi:10.1186/1479-5876-10-30
57. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348(6236):803-8; PMID:25837513; doi:10.1126/science.aaa3828
58. Vasaturo A, Halilovic A, Bol KF, Verweij DI, Blokx WA, Punt CJ, Groenen PJ, van Krieken JH, Textor J, de Vries IJ, et al. T-cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. Cancer Res 2016; 76(12):3496-506; PMID:27197179; doi:10.1158/0008-5472.CAN-15-3211
59. Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 2015; 21(10):1128-38; PMID:26444637; doi:10.1038/nm.3944
60. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20(11):1301-9; PMID:25344738; doi:10.1038/nm.3708
61. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016; 16(5):275-87; PMID:27079802; doi:10.1038/nrc.2016.36
62. Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol Immunother 2015; 64(12):1609-21; PMID:26498005; doi:10.1007/s00262-015-1766-5
63. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62(5):909-18; PMID:23589106; doi:10.1007/s00262-013-1396-8
64. Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, et al. High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Mol Med 2012; 18:1499-508; PMID:23269976; doi:10.2119/molmed.2012.00221
65. Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, Disis ML. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res 2012; 18(11):3122-31; PMID:22510348; doi:10.1158/1078-0432.CCR-12-0113
66. Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016; 6(1):71-9; PMID:26493961; doi:10.1158/2159-8290.CD-15-0510
67. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012; 4(134):134ra162; PMID:22593175; doi:10.1126/scitranslmed.3003330
68. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016; 6(2):202-16; PMID:26645196; doi:10.1158/2159-8290.CD-15-0283
69. Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, Svane IM. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide:results from a phase II trial. Cancer Immunol Immunother 2012; 61(10):1791-804; PMID:22426890; doi:10.1007/s00262-012-1242-4
70. Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med 2013; 11:135; PMID:23725550; doi:10.1186/1479-5876-11-135
71. Poschke I, Lovgren T, Adamson L, Nystrom M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 2014; 63(10):1061-71; PMID:24993563; doi:10.1007/s00262-014-1575-2
72. Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Scarpi E, Guidoboni M, Migliori G, Sanna S, et al. Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma:update of clinical outcome and subgroup analysis. Clin Dev Immunol 2010; 2010:504979; PMID:20936106; doi:10.1155/2010/504979